Profile
| Metric | Value |
|---|---|
| Full Name | Organon & Co. |
| Ticker | NYSE: OGN |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | General Drug Manufacturers |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | organon.com |
| Employees | 10,000 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $8.05 | |
| Price, 1D Change | -0.98% | |
| Market Cap | $2B | |
| TTM Dividend Yield | 4.22% | |
| PE Ratio | 4.18 | |
| Beta | 0.95 | |
| Revenue | $6B | |
| Revenue, 1Y Change | +2.24% | |
| EPS | $3.33 | |
| EPS, 1Y Change | -16.48% |
Chart
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | $0.02 | |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | OGN.V | |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | $3.33 | |
| EPS Estimate | $3.77 | |
| EPS Est. Change | +13.10% | |
| Revenue | $6.40B | |
| Revenue Estimate | $6.23B | |
| Revenue Est. Change | -2.64% | |
| Current Price | $8.05 | |
| Price Target | - | $9.00 |
| Price Tgt. Change | - | +11.80% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $4.09 | $3.99 | -2.40% | |
| $4.11 | $3.33 | -18.86% | |
| $3.77 | N/A | +13.10% | |
| $3.96 | N/A | +18.66% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $6.21B | $6.26B | +0.80% | |
| $6.41B | $6.40B | -0.06% | |
| $6.23B | N/A | -2.64% | |
| $6.18B | N/A | -3.48% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | -49.69% | |
| Price, 3Y | -72.79% | |
| Market Cap, 1Y | -49.26% | |
| Market Cap, 3Y | -72.19% | |
| Revenue, 1Y | +2.24% | |
| Revenue, 3Y | +0.68% | |
| EPS, 1Y | -16.48% | |
| EPS, 3Y | -37.43% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $8.05 | |
| SMA 200 | $9.39 | |
| SMA 200 vs Price | +16.71% | |
| SMA 50 | $7.24 | |
| SMA 50 vs Price | -10.03% | |
| Beta | 0.95 | |
| ATR | $0.34 | |
| 14-Day RSI | 65.65 | |
| 10-Day Volatility | 44.19% | |
| 1-Year Volatility | 61.73% |
Dividends
| Metric | Date | Value |
|---|---|---|
| Last Paid | $0.02 | |
| Upcoming | N/A | N/A |
| Dividend Yield | 13.91% | |
| Total Dividend | $1.12 | |
| Dividends Paid | $297.00M | |
| Payout Ratio | 34.38% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $6.40B | |
| EPS | $3.33 | |
| Gross Profit | $3.72B | |
| Gross Margin | 58.02% | |
| Operating Profit | $1.50B | |
| Operating Margin | -18.59% | |
| Net Income | $864.00M | |
| Net Margin | 13.49% | |
| EBITDA | $1.78B |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 19.14 | |
| Current Ratio | 1.60 | |
| Quick Ratio | 1.11 | |
| - | ||
| F-Score | 5 | |
| Altman Z-Score | 1.22 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 4.18 | |
| PS Ratio | 0.33 | |
| PB Ratio | 2.31 | |
| EV/EBITDA | 6.20 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $472.00M | |
| Cash & Equivalents | $675.00M | |
| Total Assets | $13.10B | |
| Current Assets | $4.35B | |
| Total Liabilities | $12.63B | |
| Current Liabilities | $2.72B | |
| Total Debt | $9.04B | |
| Short Term Debt | $64.00M | |
| Accounts Payable | $1.15B |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $5.54B | |
| Operating Expenses | $2.22B | |
| Cost Of Goods Sold | $2.69B | |
| SG&A | $0.00 | |
| D&A | $277.00M | |
| Interest Expense | $0.00 | |
| Income Tax | -$57.00M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | $939.00M | |
| CFI | -$513.00M | |
| CFF | -$368.00M | |
| Capex | $246.00M | |
| Free Cash Flow | $693.00M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Barclays | ||
| Morgan Stanley | → | |
| JP Morgan | → | |
| Piper Sandler | → | |
| Morgan Stanley | → | |
| Morgan Stanley | → | |
| Morgan Stanley | → | |
| Barclays | → | |
| JP Morgan | → | |
| Goldman Sachs | → |
Analyst sentiment
Institutional ownership
Screeners with OGN
Data Sources & References
- OGN Official Website www.organon.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1821825/000162828025050795/0001628280-25-050795-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1821825/000182182525000006/0001821825-25-000006-index.htm
- OGN Profile on Yahoo Finance finance.yahoo.com/quote/OGN
- OGN Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/ogn
FAQ
What is the ticker symbol for Organon & Co.?
The ticker symbol for Organon & Co. is NYSE:OGN
Does Organon & Co. pay dividends?
Yes, Organon & Co. pays dividends. The last payment was $0.02, with an ex-dividend date on November 20, 2025
What sector is Organon & Co. in?
Organon & Co. is in the Healthcare sector
What industry is Organon & Co. in?
Organon & Co. is in the General Drug Manufacturers industry
What country is Organon & Co. based in?
Organon & Co. is headquartered in United States
When did Organon & Co. go public?
Organon & Co. initial public offering (IPO) was on May 14, 2021
Is Organon & Co. in the S&P 500?
No, Organon & Co. is not included in the S&P 500 index
Is Organon & Co. in the NASDAQ 100?
No, Organon & Co. is not included in the NASDAQ 100 index
Is Organon & Co. in the Dow Jones?
No, Organon & Co. is not included in the Dow Jones index
When was Organon & Co. last earnings report?
Organon & Co.'s most recent earnings report was on November 10, 2025
When does Organon & Co. report earnings?
The next expected earnings date for Organon & Co. is February 12, 2026
